Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers
Open Access
- 25 April 2024
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 42 (5) , 850-868.e9
Abstract
No abstract availableKeywords
Funding Information
- Royal College of Pathologists of Australasia
- National Health and Medical Research Council
- Cass Foundation
- RCPA Foundation
- State Government of Victoria
- Victorian Cancer Agency (21006)
- Victorian Cancer Agency (17028)
- Servier
- Australian Government Department of Health and Aged Care (2023403)
This publication has 73 references indexed in Scilit:
- 1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumorsAnnals of Oncology, 2023
- Sublethal cytochrome c release generates drug-tolerant persister cellsCell, 2022
- TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid CellsCell Reports, 2020
- TP53 mutation and survival in aggressive B cell lymphomaInternational Journal of Cancer, 2017
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and ImmunityCell Reports, 2015
- An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In VivoCell Reports, 2015
- Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell DeathMolecular Cell, 2015
- Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNACell, 2014
- Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN ProductionCell, 2014